TSW
DXCM icon

Thompson Siegel & Walmsley’s DexCom DXCM Stock Holding History

Thompson Siegel & Walmsley’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-516
Closed -$64K – 411
2023
Q4 		$64K Hold
516
– – ﹤0.01% 410
2023
Q3 		$48K Buy
+516
New +$58.2K ﹤0.01% 419
2022
Q3 		– Sell
-56
Closed -$4K – 563
2022
Q2 		$4K Hold
56
– – ﹤0.01% 513
2022
Q1 		$7K Buy
+56
New +$6.13K ﹤0.01% 558
2020
Q1 		– Sell
-8,000
Closed -$437K – 681
2019
Q4 		$437K Buy
+8,000
New +$379K 0.01% 322
2015
Q2 		– Sell
-4,800
Closed -$75K – 699
2015
Q1 		$75K Buy
+4,800
New +$72.5K ﹤0.01% 456

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Thompson Siegel & Walmsley's DXCM Position: Q1 2024 in Review

Thompson Siegel & Walmsley sold out of DexCom (DXCM) in Q1 2024, closing a stake of 516 shares — an estimated $64K sold.

Thompson Siegel & Walmsley first reported a position in DXCM in Q1 2015 and held it in 6 quarters. The position peaked at $437K in Q4 2019. 1,034 funds tracked by Wall St. Rank hold DXCM as of Q1 2024.

  • Thompson Siegel & Walmsley reported no remaining DexCom position as of Q1 2024 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 516 DexCom shares in Q1 2024, an estimated $64K.
  • Thompson Siegel & Walmsley first reported a position in DexCom in Q1 2015 and held it in 6 quarters.
  • Thompson Siegel & Walmsley's DexCom position peaked at $437K in Q4 2019.
  • 1,034 funds tracked by Wall St. Rank held DexCom as of Q1 2024.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2024, filed 9 May 2024.